Signed · Germany · Pharma and biotech
Telix agrees to acquire ITM.
Telix Pharmaceuticals, based in Melbourne, Australia, signed a share purchase agreement on 21 September 2026 to acquire all shares of ITM Isotope Technologies Munich SE, a radiopharmaceutical company headquartered in Munich, Germany. Part of the price is paid in new Telix shares, and ITM shareholders would hold about 23.7 percent of Telix on completion. It was signed on 21 September 2026. It had not completed by 28 October 2026.
Signing 21 September 2026
- Buyer
- Telix Pharmaceuticals Limited ·Melbourne, Australia
- Target
- ITM Isotope Technologies Munich SE ·Munich, Germany
- Type
- Acquisition
- Announced
- 21 September 2026
- Signed
- 21 September 2026
- Value
- USD 1.65 billion upfront (cash-free, debt-free) plus conting
- People
- Not stated in the release
- Last checked
- 28 October 2026
The people side in Germany
- Above 100 employees, the economic committee is told of the change of control, the buyer and its intentions. Works Constitution Act (BetrVG), section 106
- In an asset or business transfer, staff move to the buyer on existing terms and dismissal for the transfer is invalid. Each may object within one month of being informed. Civil Code (BGB), section 613a
- Where combined worldwide turnover exceeds EUR 500 million and one party has over EUR 50 million and another over EUR 17.5 million in Germany, the deal may not complete before Bundeskartellamt clearance. Act against Restraints of Competition (GWB), sections 35, 39 and 41
- Non-EU buyers reaching 25% of a German company's votes can be screened; in 27 listed sensitive activities, 10% or 20% is notified and the deal waits for clearance. Foreign Trade and Payments Ordinance (AWV), sections 55, 55a and 56, with Foreign Trade and Payments Act (AWG), section 15
- An employer with staff in German social insurance obtains a company number (Betriebsnummer) for each establishment; an employer without a seat in Germany also appoints a representative based there. Social Code Book IV (SGB IV), sections 18i and 28f(1b)
- Where the deal needs EU merger clearance, the buyer may not implement it before clearance. EU Merger Regulation (Council Regulation (EC) No 139/2004), article 7
Related deals
- 26 Oct
Main Capital Partnersto
4ALLPORTAL GmbHdeal page: Main Capital Partners takes a majority stake in 4ALLPORTALCompleted
not statedSigningDay 100 - 23 Oct
Indutrade ABto
Schraner GmbHdeal page: Indutrade acquires SchranerCompleted
35SigningDay 100 - 20 Oct
Ambrose Healthcareto
AM-Pharma B.V.deal page: Ambrose Healthcare acquires AM-PharmaCompleted
not statedSigningDay 100 - 19 Oct
Merck KGaAto
Silence Therapeutics plcdeal page: Merck KGaA agrees to acquire Silence TherapeuticsSigned
not statedSigningDay 100